Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

Results of a west Japan oncology group study

Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita, Masahiko Ando, Koji Takeda, Takashi Seto, Nobuyuki Yamamoto, Hideo Saka, Kazuhiro Asami, Tomonori Hirashima, Shinzoh Kudoh, Miyako Satouchi, Norihiko Ikeda, Yasuo Iwamoto, Toshiyuki Sawa, Masaki Miyazaki, Kenji Tamura, Takayasu Kurata, Masahiro Fukuoka, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Purpose: The primary goal of this open-label, multicenter, randomized phase III trial was to determine whether treatment with carboplatin plus the oral fluoropyrimidine derivative S-1 was noninferior versus that with carboplatin plus paclitaxel with regard to overall survival (OS) in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: A total of 564 patients were randomly assigned to receive either carboplatin (area under the curve, 5) on day 1 plus oral S-1 (40 mg/m 2 twice per day) on days 1 to 14 or carboplatin (area under the curve, 6) plus paclitaxel (200 mg/m 2) on day 1 every 21 days. Results: At the planned interim analysis, with a total of 268 death events available, the study passed the O'Brien-Fleming boundary of 0.0080 for a positive result and noninferiority of carboplatin and S-1 compared with carboplatin and paclitaxel was confirmed for OS (hazard ratio, 0.928; 99.2% CI, 0.671 to 1.283). Median OS was 15.2 months in the carboplatin and S-1 arm and 13.3 months in the carboplatin and paclitaxel arm, with 1-year survival rates of 57.3% and 55.5%, respectively. Rates of leukopenia or neutropenia of grade 3/4, febrile neutropenia, alopecia, and neuropathy were more frequent in the carboplatin and paclitaxel arm, whereas thrombocytopenia, nausea, vomiting, and diarrhea were more common in the carboplatin and S-1 arm. The carboplatin and S-1 arm had significantly more dose delays than the carboplatin and paclitaxel arm. Conclusion: Oral S-1 with carboplatin was noninferior in terms of OS compared with carboplatin and paclitaxel in patients with advanced NSCLC, and is thus a valid treatment option.

Original languageEnglish
Pages (from-to)5240-5246
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number36
DOIs
Publication statusPublished - Dec 20 2010
Externally publishedYes

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Japan
Drug Therapy
Survival
Area Under Curve
Febrile Neutropenia
Alopecia
Leukopenia
Neutropenia
Thrombocytopenia
Nausea
Vomiting
Diarrhea

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer : Results of a west Japan oncology group study. / Okamoto, Isamu; Yoshioka, Hiroshige; Morita, Satoshi; Ando, Masahiko; Takeda, Koji; Seto, Takashi; Yamamoto, Nobuyuki; Saka, Hideo; Asami, Kazuhiro; Hirashima, Tomonori; Kudoh, Shinzoh; Satouchi, Miyako; Ikeda, Norihiko; Iwamoto, Yasuo; Sawa, Toshiyuki; Miyazaki, Masaki; Tamura, Kenji; Kurata, Takayasu; Fukuoka, Masahiro; Nakagawa, Kazuhiko.

In: Journal of Clinical Oncology, Vol. 28, No. 36, 20.12.2010, p. 5240-5246.

Research output: Contribution to journalArticle

Okamoto, I, Yoshioka, H, Morita, S, Ando, M, Takeda, K, Seto, T, Yamamoto, N, Saka, H, Asami, K, Hirashima, T, Kudoh, S, Satouchi, M, Ikeda, N, Iwamoto, Y, Sawa, T, Miyazaki, M, Tamura, K, Kurata, T, Fukuoka, M & Nakagawa, K 2010, 'Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: Results of a west Japan oncology group study', Journal of Clinical Oncology, vol. 28, no. 36, pp. 5240-5246. https://doi.org/10.1200/JCO.2010.31.0326
Okamoto, Isamu ; Yoshioka, Hiroshige ; Morita, Satoshi ; Ando, Masahiko ; Takeda, Koji ; Seto, Takashi ; Yamamoto, Nobuyuki ; Saka, Hideo ; Asami, Kazuhiro ; Hirashima, Tomonori ; Kudoh, Shinzoh ; Satouchi, Miyako ; Ikeda, Norihiko ; Iwamoto, Yasuo ; Sawa, Toshiyuki ; Miyazaki, Masaki ; Tamura, Kenji ; Kurata, Takayasu ; Fukuoka, Masahiro ; Nakagawa, Kazuhiko. / Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer : Results of a west Japan oncology group study. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 36. pp. 5240-5246.
@article{43ae91bcb1db425783162f8a6cfd87de,
title = "Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-na{\"i}ve patients with advanced non-small-cell lung cancer: Results of a west Japan oncology group study",
abstract = "Purpose: The primary goal of this open-label, multicenter, randomized phase III trial was to determine whether treatment with carboplatin plus the oral fluoropyrimidine derivative S-1 was noninferior versus that with carboplatin plus paclitaxel with regard to overall survival (OS) in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: A total of 564 patients were randomly assigned to receive either carboplatin (area under the curve, 5) on day 1 plus oral S-1 (40 mg/m 2 twice per day) on days 1 to 14 or carboplatin (area under the curve, 6) plus paclitaxel (200 mg/m 2) on day 1 every 21 days. Results: At the planned interim analysis, with a total of 268 death events available, the study passed the O'Brien-Fleming boundary of 0.0080 for a positive result and noninferiority of carboplatin and S-1 compared with carboplatin and paclitaxel was confirmed for OS (hazard ratio, 0.928; 99.2{\%} CI, 0.671 to 1.283). Median OS was 15.2 months in the carboplatin and S-1 arm and 13.3 months in the carboplatin and paclitaxel arm, with 1-year survival rates of 57.3{\%} and 55.5{\%}, respectively. Rates of leukopenia or neutropenia of grade 3/4, febrile neutropenia, alopecia, and neuropathy were more frequent in the carboplatin and paclitaxel arm, whereas thrombocytopenia, nausea, vomiting, and diarrhea were more common in the carboplatin and S-1 arm. The carboplatin and S-1 arm had significantly more dose delays than the carboplatin and paclitaxel arm. Conclusion: Oral S-1 with carboplatin was noninferior in terms of OS compared with carboplatin and paclitaxel in patients with advanced NSCLC, and is thus a valid treatment option.",
author = "Isamu Okamoto and Hiroshige Yoshioka and Satoshi Morita and Masahiko Ando and Koji Takeda and Takashi Seto and Nobuyuki Yamamoto and Hideo Saka and Kazuhiro Asami and Tomonori Hirashima and Shinzoh Kudoh and Miyako Satouchi and Norihiko Ikeda and Yasuo Iwamoto and Toshiyuki Sawa and Masaki Miyazaki and Kenji Tamura and Takayasu Kurata and Masahiro Fukuoka and Kazuhiko Nakagawa",
year = "2010",
month = "12",
day = "20",
doi = "10.1200/JCO.2010.31.0326",
language = "English",
volume = "28",
pages = "5240--5246",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

T2 - Results of a west Japan oncology group study

AU - Okamoto, Isamu

AU - Yoshioka, Hiroshige

AU - Morita, Satoshi

AU - Ando, Masahiko

AU - Takeda, Koji

AU - Seto, Takashi

AU - Yamamoto, Nobuyuki

AU - Saka, Hideo

AU - Asami, Kazuhiro

AU - Hirashima, Tomonori

AU - Kudoh, Shinzoh

AU - Satouchi, Miyako

AU - Ikeda, Norihiko

AU - Iwamoto, Yasuo

AU - Sawa, Toshiyuki

AU - Miyazaki, Masaki

AU - Tamura, Kenji

AU - Kurata, Takayasu

AU - Fukuoka, Masahiro

AU - Nakagawa, Kazuhiko

PY - 2010/12/20

Y1 - 2010/12/20

N2 - Purpose: The primary goal of this open-label, multicenter, randomized phase III trial was to determine whether treatment with carboplatin plus the oral fluoropyrimidine derivative S-1 was noninferior versus that with carboplatin plus paclitaxel with regard to overall survival (OS) in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: A total of 564 patients were randomly assigned to receive either carboplatin (area under the curve, 5) on day 1 plus oral S-1 (40 mg/m 2 twice per day) on days 1 to 14 or carboplatin (area under the curve, 6) plus paclitaxel (200 mg/m 2) on day 1 every 21 days. Results: At the planned interim analysis, with a total of 268 death events available, the study passed the O'Brien-Fleming boundary of 0.0080 for a positive result and noninferiority of carboplatin and S-1 compared with carboplatin and paclitaxel was confirmed for OS (hazard ratio, 0.928; 99.2% CI, 0.671 to 1.283). Median OS was 15.2 months in the carboplatin and S-1 arm and 13.3 months in the carboplatin and paclitaxel arm, with 1-year survival rates of 57.3% and 55.5%, respectively. Rates of leukopenia or neutropenia of grade 3/4, febrile neutropenia, alopecia, and neuropathy were more frequent in the carboplatin and paclitaxel arm, whereas thrombocytopenia, nausea, vomiting, and diarrhea were more common in the carboplatin and S-1 arm. The carboplatin and S-1 arm had significantly more dose delays than the carboplatin and paclitaxel arm. Conclusion: Oral S-1 with carboplatin was noninferior in terms of OS compared with carboplatin and paclitaxel in patients with advanced NSCLC, and is thus a valid treatment option.

AB - Purpose: The primary goal of this open-label, multicenter, randomized phase III trial was to determine whether treatment with carboplatin plus the oral fluoropyrimidine derivative S-1 was noninferior versus that with carboplatin plus paclitaxel with regard to overall survival (OS) in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: A total of 564 patients were randomly assigned to receive either carboplatin (area under the curve, 5) on day 1 plus oral S-1 (40 mg/m 2 twice per day) on days 1 to 14 or carboplatin (area under the curve, 6) plus paclitaxel (200 mg/m 2) on day 1 every 21 days. Results: At the planned interim analysis, with a total of 268 death events available, the study passed the O'Brien-Fleming boundary of 0.0080 for a positive result and noninferiority of carboplatin and S-1 compared with carboplatin and paclitaxel was confirmed for OS (hazard ratio, 0.928; 99.2% CI, 0.671 to 1.283). Median OS was 15.2 months in the carboplatin and S-1 arm and 13.3 months in the carboplatin and paclitaxel arm, with 1-year survival rates of 57.3% and 55.5%, respectively. Rates of leukopenia or neutropenia of grade 3/4, febrile neutropenia, alopecia, and neuropathy were more frequent in the carboplatin and paclitaxel arm, whereas thrombocytopenia, nausea, vomiting, and diarrhea were more common in the carboplatin and S-1 arm. The carboplatin and S-1 arm had significantly more dose delays than the carboplatin and paclitaxel arm. Conclusion: Oral S-1 with carboplatin was noninferior in terms of OS compared with carboplatin and paclitaxel in patients with advanced NSCLC, and is thus a valid treatment option.

UR - http://www.scopus.com/inward/record.url?scp=79951911908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951911908&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.31.0326

DO - 10.1200/JCO.2010.31.0326

M3 - Article

VL - 28

SP - 5240

EP - 5246

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -